MoFo partner Chuan Sun was quoted in an article titled "BrightGene Responds to Two Major Questions About the “Weight-Loss Drug” Deal."
The article reports on BrightGene’s grant of domestic commercialization rights for its GLP-1 drug candidate to China Resources Sanjiu Medical & Pharmaceutical and the firm’s responses to market concerns about the deal's valuation and partner choice.
It also discusses the surging interest and high-value licensing deals in the GLP-1 sector for diabetes and weight-loss drugs, driven by blockbuster products from global giants including Novo Nordisk and Eli Lilly.
Chuan provides insight into the general factors influencing the amounts in BD licensing deals.